Ward Peterson joined Symberix in late 2013 after realizing that the company had potential to make unprecedented strides in the field of biopharmaceuticals. Symberix, based in Durham, is a preclinical stage company working toward the development of first-in-class pharmaceutical treatments for intestinal disorders.
Still in its early stages, the company hopes to pioneer the discovery of a new class of drugs designed to safely and selectively and safely target bacteria found in the gut microbiome.
Symberix was founded as a North Carolina company in 2013 by Peterson, a scientist with over 20 years of research and development experience in pharma and biotech, and Dr. Matthew Redinbo, a Kenan Distinguished professor at UNC-Chapel Hill and former chair of the school’s chemistry department.
Through UNC Kickstart Ventures, Peterson connected with Redinbo, who originally developed the microbiome-based technology that was first published in 2010 in the prestigious journal Science.
Read the full story via the North Carolina Business News Wire, a service of the UNC-Chapel Hill School of Media and Journalism.
| UNC-CH